Blueprint Medicines Corporation operates as a global biopharmaceutical company that develops medicines for genomically defined cancers, blood disorders, and allergy/inflammation in the United States and internationally. The company develops AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company develops BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. Blueprint Medicines Corporation was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. The company was incorporated in 2008 and is based in Cambridge, Massachusetts. As of July 18, 2025, Blueprint Medicines Corporation operates as a subsidiary of Sanofi. Show more

Location: 45 Sidney Street, Cambridge, MA, 02139, United States | Website: https://www.blueprintmedicines.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

8.372B

52 Wk Range

$73.04 - $129.65

Previous Close

$129.46

Open

$129.46

Volume

N/A

Day Range

$129.46 - $129.46

Enterprise Value

8.251B

Cash

576.2M

Avg Qtr Burn

-36.39M

Insider Ownership

0.87%

Institutional Own.

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AYVAKIT (avapritinib) Details PDGFRA mutant GIST (Gastrointestinal Stromal Tumors)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AYVAKIT® (avapritinib) Details Systemic Mastocytosis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GAVRETO (parlsetinib) Details Non-small cell lung carcinoma, Thyroid cancer, Cancer, Solid tumor/s	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BLU-808 Details Chronic urticaria, CSU/CInDu, allergic rhinitis/allergic conjunctivitis	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BLU-222 (CDK12) Details Breast cancer, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elenestinib Details Systemic Mastocytosis	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BLU-451 Details Non-small cell lung carcinoma, Cancer, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BLU-945 +/- osimertinib Details Cancer, Solid tumor/s, Non-small cell lung carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.